| Target Price | $10.71 |
| Price | $1.86 |
| Potential |
475.81%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Rani Therapeutics Holdings Inc - Ordinary Shares Class A 2026 .
The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A target price is $10.71.
This is
475.81%
register free of charge
$12.60
577.42%
register free of charge
$9.09
388.71%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Rani Therapeutics Holdings Inc - Ordinary Shares Class A to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rani Therapeutics Holdings Inc - Ordinary Shares Class A stock has an average upside potential 2026 of
475.81%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.03 | 0.19 |
| 81.12% | ||
| EBITDA Margin | -4,715.53% | -27,692.35% |
| 487.26% | ||
| Net Margin | -2,914.56% | -13,039.49% |
| 347.39% |
6 Analysts have issued a sales forecast Rani Therapeutics Holdings Inc - Ordinary Shares Class A 2025 . The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Rani Therapeutics Holdings Inc - Ordinary Shares Class A EBITDA forecast 2025. The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | -4,715.53% | |
|---|---|---|
| 2025 |
-27,692.35%
487.26%
Unlock
|
|
6 Rani Therapeutics Holdings Inc - Ordinary Shares Class A Analysts have issued a net profit forecast 2025. The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.05 | -0.40 |
| 21.05% | 61.90% | |
| P/E | negative | |
| EV/Sales | 723.40 |
6 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast for earnings per share. The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A EPS is
This results in the following potential growth metrics and future valuations:
Rani Therapeutics Holdings Inc - Ordinary Shares Class A...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Maxim Group |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Maxim Group:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 18 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


